Long-term efficacy of endoscopic treatment for patients with gastric submucosal tumor

Abstract

Objective To study the value of endoscopic treatment for patients with gastric submucosal tumor (G-SMT). Methods The data of 1 663 patients with G-SMT undergoing endoscopic treatment was retrospective reviewed from January 2008 to December 2013. Patients′ demographics, treatment outcomes, and follow-up were evaluated. Results A total of 1 671 lesions of G-SMT were included in the study. The mean maximum size of lesions was (1.50±1.02) cm. Twenty lesions were treated by endoscopic mucosal resection, 296 lesions by endoscopic submucosal dissection (ESD), 7 lesions by ESD+ nylon endoloop, 1 011 lesions by endoscopic submucosal excavation, 44 lesions by submucosal tunneling endoscopic resection, and 285 lesions by endoscopic full-thickness resection. Endoscopic treatment failed in 8 cases. Postoperative pathology diagnosis included 554 liomyoma, 485 gastrointestinal stromal tumors, 160 ectopic pancreas, and other such as lipoma, neuroendocrine tumor and fibroma. There were 16 cases of bleeding and 18 cases of perforation after treatment. Except for 4 cases of bleeding and 2 cases of perforation underwent additional surgical procedures, all patients were managed by conservative treatments. During a median follow-up time of 36 months of 1 226 cases, the recurrence rate was 1%(12/1 226), and no death occurred. Conclusion Endoscopic treatment is safe and effective in treating G-SMT for long-term outcomes. Key words: Stomach neoplasms; Endoscopes, therapy; Validation studies; Safety; Submucosal tumor